ArticleCureus2026
Improving Lipid Screening Adherence in Inflammatory Arthritis Using a Two-Cycle Plan-Do-Study-Act (PDSA) Quality Improvement Intervention.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoimmune diseases, such as rheumatoid arthritis (RA) and spondylarthritis (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), are characterized by chronic systemic inflammation and are associated with significant cardiovascular morbidity and mortality. Dyslipidemia is a well-established contributor to this increased cardiovascular risk and represents an important comorbidity in patients with rheumatologic disease. STUDY
aimThis pre-post interventional quality improvement (QI) study used two iterative Plan-Do-Study-Act (PDSA) cycles at a high-volume, academic rheumatology clinic to improve provider adherence to lipid screening guidelines for patients with seropositive RA, PsA, or AS, as determined by International Classification of Diseases 10th Revision (ICD-10) codes. Patients were excluded if they had a diagnosis of systemic lupus erythematosus (SLE), juvenile dermatomyositis, Sjogren syndrome, or arthropathic psoriasis, or if they were managed at other rheumatology clinics within the Houston Methodist system.
methodsBaseline screening rates were established via retrospective chart review between July 2024 and February 2025. PDSA Cycle 1 spanned from March to April of 2025 and involved the deployment of provider education, physical and email reminders, and a custom Epic dot phrase. PDSA Cycle 2 spanned from April to May of 2025 and consisted of pre-visit chart review and the placement of a pending lipid panel into the electronic health record (EHR) if needed. The primary outcome was the percentage of eligible patients with a completed lipid panel in the preceding 12 months.
resultsRetrospective chart review at baseline indicated a care gap, with 62.4% (98/157) of eligible patients having completed a lipid panel within the prior 12 months. Interventions for PDSA Cycle 1 resulted in the rheumatology providers ordering two lipid panels for patients, yet the total screening rate with the intervention was 57.1% (28/49), lower than baseline. The process interventions in PDSA Cycle 2 drastically increased the lipid screening rate to 92.8% (13/14).
conclusionsThe QI initiative demonstrated that system-level workflow interventions incorporating pre-visit chart review and preemptive order entry were associated with improved lipid screening adherence among patients with RA, PsA, and AS. Educational interventions and passive EHR-based tools alone did not result in sustained improvement. These findings highlight the importance of embedding preventive care measures directly into clinical workflows to improve adherence to cardiovascular risk screening guidelines in rheumatology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.